Shareholders to Vote on Highly Dilutive Financing and Oratech Acquisition, Resulting in 88% Dilution

summarizeSummary

Lifeward Ltd. has filed a definitive proxy statement for an Extraordinary General Meeting to seek shareholder approval for a highly dilutive financing package and the acquisition of Oratech Pharma, which will result in approximately 88% dilution to existing shareholders on a fully-diluted basis.

check_boxKey Events

• Shareholder Vote on Major Dilution

  Shareholders will vote on the issuance of approximately 131 million ordinary shares, leading to an estimated 88% dilution for existing shareholders on a fully-diluted basis.

• Critical Financing for Operations

  The proposed financing is essential to repay a $3.0 million secured note and fund operations beyond Q1 2026, highlighting the company's urgent capital needs.

• Acquisition of Oratech Pharma

  The financing is tied to the acquisition of Oratech Pharma, Inc., which will make Oramed a controlling shareholder and trigger Nasdaq change of control rules.

• Discounted Share Issuance

  Shares, convertible notes, and warrants are being issued at a conversion/exercise price of $0.45, below the current market price, triggering Nasdaq Listing Rule 5635(d)(2).

auto_awesomeAnalysis

This definitive proxy statement finalizes the terms for a critical shareholder vote on a series of transactions previously announced in preliminary filings. The core proposal involves the issuance of approximately 131 million ordinary shares to Oramed Pharmaceuticals Inc. as consideration for the Oratech Pharma acquisition and related financing. This transaction is projected to dilute existing shareholders by approximately 88% on a fully-diluted basis, with Oramed potentially holding over 49.99% of the company's voting power. The financing includes secured convertible notes and warrants with a conversion/exercise price of $0.45 per share, significantly below the current market price of $0.5509. The company explicitly states that approval is necessary to repay a $3.0 million secured promissory note maturing in May 2026 and to continue operations beyond Q1 2026, underscoring the distressed nature of this capital raise. Additionally, shareholders will vote on a substantial increase in the incentive compensation plan (5.2 million shares) and a large equity grant to the CEO (5% of post-acquisition shares), further contributing to dilution. The transaction will also trigger changes in corporate governance due to Oramed becoming a controlling shareholder under Israeli law.